Cotempla Xr-odt Tablet, Orally Disintegrating
Product Images NDC 70165-200

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cotempla Xr-odt (NDC 70165-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Neos Therapeutics Brands, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Cotempla Xr Odt 1)

Chemical structure of methylphenidate displayed as a 2D molecular diagram showing a piperidine ring, methyl ester group, and phenyl ring linked to the central carbon.*

FDA Label Image

Figure 2 (Cotempla Xr Odt 2)

A line graph comparing mean d-Methylphenidate plasma concentration (ng/mL) over time (hours) for Cotempla XR-ODT 2x25.9 mg tablets and Methylphenidate Hydrochloride Extended Release Capsules 60 mg. The graph shows plasma concentration changes from 0 to 36 hours, with both formulations exhibiting a peak around 4-6 hours and gradually declining thereafter.*

FDA Label Image

Figure 3 (Cotempla Xr Odt 3)

A line graph comparing the mean SKAMP Combined Scores over time (hours) for Cotempla XR-ODT and placebo. The x-axis indicates time points from pre-dose to 13 hours, and the y-axis shows mean SKAMP Combined Score ± SE. Cotempla XR-ODT scores decrease sharply after dosing, reaching a minimum around 3 hours, then gradually increase. The placebo scores remain relatively steady with a slight upward trend over time.*

FDA Label Image

Principal Display Panel (8.6 mg Tablet Blister Pack Carton)

The image shows the packaging label for Cotempla XR-ODT 8.6 mg methylphenidate extended-release orally disintegrating tablets by Neos Therapeutics Brands LLC. The label includes dosage strength, tablet count (30 tablets in 5 blister cards), storage instructions, inactive ingredients, and usage handling details.*

FDA Label Image

Principal Display Panel (17.3 mg Tablet Blister Pack Carton)

Packaging label for Cotempla XR-ODT 17.3 mg extended-release orally disintegrating tablets. The label shows the brand name, methylphenidate as the active ingredient, and includes dosage form details. It states 'Do not crush or chew tablets' and indicates 30 tablets in 5 blister cards plus a travel case. Manufactured by Neos Therapeutics Brands, LLC, the label includes storage instructions, lot and expiration placeholders, and instructions for use.*

FDA Label Image

Principal Display Panel (25.9 mg Tablet Blister Pack Carton)

The packaging label for Cotempla XR-ODT 25.9 mg tablets features the brand and generic names prominently, indicating methylphenidate extended-release orally disintegrating tablets. The label shows the dosage strength of 25.9 mg, along with storage instructions, manufacturer details (Neos Therapeutics Brands LLC), and blister pack information. Warnings about not crushing or chewing the tablets and directions for removal are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.